TheStreet’s Jim Cramer answers viewer questions from social media on the floor of the New York Stock Exchange. There was plenty of talk about Ambarella (AMBA), the HD video processing company dropped 40 percent since summer. ‘Ambarella is very linked to GoPro (GPRO),’ he said. ‘There’s a survey out by Piper Jaffray saying that teens don’t like using GoPro, which means Ambarella takes another hit.’ With Ferrari gearing up to go public, investors are eyeing the stock. ‘Ferrari is going to be an interesting opportunity because everyone’s going to like a stock by the name of RACE,’ said Cramer. With the holidays coming up, travel stocks are coming into focus. Trip Advisor (TRIP) is making headlines after forging a room booking deal with Priceline (PCLN). Customers will now be able to book hotel rooms directly through the travel review website. Cramer is pro the idea. ‘Trip Advisor and Priceline deserve to be one company, that’s how seamless this will make them,’ he said. ‘I like Expedia (EXPE) too.’ Other questions from viewers touched on the pharmaceutical industry. Rumors have been circulating that Pfizer (PFE) may buyout Allergan (AGN) once the company’s deal with Teva Pharmaceuticals (TEVA) has been completed.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.